摘要
应用免疫组化技术检测了30例乳腺导管上皮增生(增生组,其中一般增生18例,不典型增生12例)、40例导管癌(癌组)和20例正常副乳腺(正常组)患者的p^(53)和c-erbB-2癌基因产物的表达及其分布。结果;增生组、癌组和正常的p^(53)蛋白阳性表达率分别为0、17.5％和0,c-erbB-2蛋白阳性表达率分别为26.7％,37.5％和0,三组间差异显著(均P<0.005)。并且增生组中不典型增生的c-erbB-2蛋白阳性率(50％)显著高于一般增生(11.1％,P<0.05)。提示c-erbB-2和p^(53)的检测在评估乳腺导管上皮不典型增生及其恶变潜能方面可能具有一定的参考价值。
Thirty cases of breast intraductal hyperplasia(IDH) including ordinary IDH(OIDH)18 cases and atypical IDH(AIDH)12 cases,40 cases of ductal carcinoma (DCa) and 20 cases of normal accessory breast (NAB) were examined to observe the expression and distribution of P53and c-erbB-2 oncoproteins by immunohistochemistry technique. The positive exprssions in IDH.DCa and NAB groups for P53 oncoprotin were 0,17. 5% and 0 respectively,for c-erbB-2 oncoprotein were 26. 7%, 37. 5% and 0 respectively,the differences among 3 groups were siginficant(P<0. 005 for all). The positive expression of c-erbB-2 oncoprtein in AIDH (50%) was significantly higher than in OIDH (11. 1 % ,P<0. 05). C-erbB-2 and P53 oncoproteins may be a valuable marker in evaluating breast AIDH and its potentiality of malignant change.
出处
《天津医药》
CAS
1996年第8期467-470,共4页
Tianjin Medical Journal
基金
国家教委优秀青年教师基金
关键词
乳腺肿瘤
不典型增生
breast carcinoma atypical intraductal hyperplasia gene expression immuno- histochemistry
